Spry Review
Best for: Buyers seeking a multi-product wellness/longevity platform that combines compounded GLP-1s with anti-aging peptides under one membership, who are comfortable with nurse-practitioner intake review (vs MD) and willing to overlook the 'FDA Approved' badge framing on a compounded-medication platform.
Spry (becomespry.com) is a weight-loss + anti-aging telehealth platform offering 5 products: compounded semaglutide ($199/mo starting), compounded tirzepatide ($299/mo starting), BPC-157 peptide ($249/mo), NAD+ ($299/mo), and sermorelin ($249/mo). Tagline: 'Simple Medical Treatments / Your best body.' Three named co-founders: Gabriel Mullins, Sara Yoder, Tyler Bowman. Team claims '20+ years of experience.' Patient intake reviewed by nurse practitioner within 24 hours (verbatim FAQ: 'Our nurse practitioner will review your file within 24 hours'). LegitScript Certified — verification link goes to legitscript.com/websites/?checker_keywords=becomespry.com but specific ID number is not displayed on the homepage. Site also displays an 'FDA Approved' badge — buyers should note that COMPOUNDED semaglutide and tirzepatide are NOT FDA-approved finished drug products (the API may be FDA-approved as a substance, but the compounded preparation is not), so this badge framing warrants careful interpretation. No insurance accepted. No contracts or commitments. Captured via Chrome MCP since site is JS-rendered SPA. States served, pharmacy partner, 503A vs 503B designation, FDA compounded-medication disclaimer text, governing law, and corporate legal entity (LLC/Inc/PC) are NOT publicly disclosed. Live-verified 2026-05-19.
Medium confidence · Last verified 2026-05-19 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Spry is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Spry prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Starting tier | compounded | $199 |
| Starting tier | compounded | $299 |
✓ Pros
- •Three named co-founders explicitly disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency vs anonymous DTC competitors
- •Pricing tier disclosed on homepage ($199 semaglutide / $299 tirzepatide / $249-$299 peptides) — no full sign-up wall
- •Broader product range (2 GLP-1s + 3 anti-aging peptides) appeals to longevity-buyer segment
- •No contracts or commitment requirements per FAQ
- •LegitScript Certified with public verification link
- •Same-day-24hr provider review intake speed
✗ Cons
- •**YMYL CONCERN**: Site displays an 'FDA Approved' badge while selling compounded semaglutide and tirzepatide — compounded preparations are NOT FDA-approved finished drug products. This framing is potentially misleading vs the WLR transparency standard. The verbatim FDA compounded-medication disclaimer used by transparent competitors (e.g., 'compounded medications are not FDA-approved as a finished drug product') is absent from the homepage.
- •LegitScript ID NUMBER not publicly displayed on the homepage (only the verification link)
- •Intake reviewed by NURSE PRACTITIONER (per FAQ verbatim) — not MD review like Rewinding RX's positioning
- •States-served list NOT disclosed publicly
- •Pharmacy partner NOT named
- •503A vs 503B compounding designation NOT specified
- •Corporate legal entity (LLC/Inc/PC) NOT disclosed
- •Site is fully JavaScript-rendered SPA — pricing + nav captured only via Chrome MCP, not WebFetch
- •Co-founder credentials (medical or otherwise) not disclosed in the team section
- •BPC-157 peptide is an unregulated longevity supplement with limited human efficacy data — its inclusion alongside FDA-recognized weight-loss compounded GLP-1s reflects the broader functional-medicine positioning vs evidence-grade weight-loss specialist
Ready to start with Spry?
Starting at $199/month. See current pricing and start your free consultation.
Sources & methodology
Our Spry review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Spry
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Spry?
Starting at $199/month. See current pricing and start your free consultation.